<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/semaglutide-ve-kalp-sagligi-select-calismasi-sonuclari.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/semaglutide-ve-kalp-sagligi-select-calismasi-sonuclari.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ± | UzunYaÅŸa Blog</title>
    <meta name="description" content="SELECT Ã§alÄ±ÅŸmasÄ± sonuÃ§larÄ±: Semaglutide'nin kalp-damar hastalÄ±klarÄ± Ã¼zerindeki etkisi ve kilo verme ile kardiyovaskÃ¼ler saÄŸlÄ±k arasÄ±ndaki baÄŸlantÄ±.">
    <meta property="og:title" content="Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ±">
    <meta property="og:description" content="SELECT Ã§alÄ±ÅŸmasÄ± sonuÃ§larÄ±: Semaglutide'nin kalp-damar hastalÄ±klarÄ± Ã¼zerindeki etkisi ve kilo verme ile kardiyovaskÃ¼ler saÄŸlÄ±k arasÄ±ndaki baÄŸlantÄ±.">
    <meta property="og:image" content="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=600&fit=crop">
    <meta property="og:type" content="article">
    <meta property="article:published_time" content="2026-02-12">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary: #195157;
            --accent: #E8963E;
            --text: #1a1a1a;
            --gray: #6b7280;
            --bg: #FAF9F7;
            --white: #FFFFFF;
            --border: #e5e7eb;
            --category-color: #8B5CF6;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Inter', sans-serif; color: var(--text); line-height: 1.8; background: var(--bg); }
        .header { position: fixed; top: 0; left: 0; right: 0; z-index: 1000; background: rgba(255,255,255,0.97); backdrop-filter: blur(10px); border-bottom: 1px solid var(--border); }
        .header-inner { max-width: 1200px; margin: 0 auto; padding: 0.75rem 2rem; display: flex; align-items: center; justify-content: space-between; }
        .logo-img { height: 60px; }
        .back-link { color: var(--primary); text-decoration: none; font-weight: 500; }
        .back-link:hover { text-decoration: underline; }
        article { max-width: 750px; margin: 0 auto; padding: 7rem 1.5rem 4rem; }
        .post-category { display: inline-block; background: #8B5CF620; color: #8B5CF6; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.85rem; font-weight: 600; margin-bottom: 1rem; }
        h1 { font-size: 2.25rem; font-weight: 700; line-height: 1.3; margin-bottom: 1rem; }
        .post-meta { color: var(--gray); font-size: 0.9rem; display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 2rem; }
        .featured-image { width: 100%; height: 350px; border-radius: 16px; overflow: hidden; margin-bottom: 2.5rem; }
        .featured-image img { width: 100%; height: 100%; object-fit: cover; }
        .post-content { font-size: 1.1rem; }
        .post-content h2 { font-size: 1.5rem; margin: 2.5rem 0 1rem; color: var(--primary); }
        .post-content h3 { font-size: 1.25rem; margin: 2rem 0 0.75rem; }
        .post-content p { margin-bottom: 1.25rem; }
        .post-content ul, .post-content ol { margin: 1rem 0 1.5rem 1.5rem; }
        .post-content li { margin-bottom: 0.5rem; }
        .post-content blockquote { border-left: 4px solid var(--accent); padding-left: 1.5rem; margin: 1.5rem 0; font-style: italic; color: var(--gray); }
        .post-content strong { color: var(--primary); }
        .key-points { background: var(--white); border: 2px solid var(--border); border-radius: 12px; padding: 1.5rem 1.5rem 1.5rem 2rem; margin: 2.5rem 0; }
        .key-points h4 { color: var(--primary); margin-bottom: 1rem; font-size: 1.1rem; }
        .key-points ul { margin: 0; }
        .key-points li { margin-bottom: 0.5rem; }
        .sources { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); }
        .sources h4 { font-size: 1rem; margin-bottom: 0.75rem; color: var(--primary); }
        .sources ul { list-style: none; margin: 0; padding: 0; }
        .sources li { font-size: 0.9rem; color: var(--gray); margin-bottom: 0.5rem; }
        .sources a { color: var(--primary); }
        .disclaimer { background: #FEF3C7; border: 1px solid #F59E0B; border-radius: 8px; padding: 1rem; margin-top: 2rem; font-size: 0.9rem; color: #92400E; }
        .share-section { margin-top: 3rem; padding: 2rem; background: var(--white); border-radius: 12px; text-align: center; border: 1px solid var(--border); }
        .share-buttons { display: flex; gap: 0.75rem; justify-content: center; margin-top: 1rem; flex-wrap: wrap; }
        .share-btn { padding: 0.65rem 1.25rem; border-radius: 8px; text-decoration: none; font-weight: 500; font-size: 0.9rem; color: white; }
        .share-btn.twitter { background: #1DA1F2; }
        .share-btn.linkedin { background: #0A66C2; }
        .share-btn.whatsapp { background: #25D366; }
        .cta-section { margin-top: 3rem; padding: 2rem; background: linear-gradient(135deg, var(--primary), #2a6b73); border-radius: 12px; text-align: center; color: white; }
        .cta-section h3 { margin-bottom: 0.5rem; }
        .cta-section p { opacity: 0.9; margin-bottom: 1rem; }
        .cta-btn { display: inline-block; background: var(--accent); color: white; padding: 0.875rem 2rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
        footer { background: var(--text); color: white; padding: 2rem; text-align: center; margin-top: 4rem; }
        footer p { opacity: 0.7; font-size: 0.9rem; }
        @media (max-width: 640px) { h1 { font-size: 1.65rem; } article { padding: 5.5rem 1rem 2rem; } .featured-image { height: 220px; } }
    </style>
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/semaglutide-ve-kalp-sagligi-select-calismasi-sonuclari.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ± | UzunYaÅŸa Blog",
  "description": "SELECT Ã§alÄ±ÅŸmasÄ± sonuÃ§larÄ±: Semaglutide",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-12",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/semaglutide-ve-kalp-sagligi-select-calismasi-sonuclari.html",
  "image": "https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=600&fit=crop"
}
</script>
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@uzunyasaorg">
    <meta name="twitter:title" content="Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ± | UzunYaÅŸa Blog">
    <meta name="twitter:description" content="SELECT Ã§alÄ±ÅŸmasÄ± sonuÃ§larÄ±: Semaglutide">
    <meta name="twitter:image" content="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=600&fit=crop">
  </head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
            <a href="../blog.html" class="back-link">â† Blog'a DÃ¶n</a>
        </div>
    </header>

    <article>
        <span class="post-category">ğŸ§¬ Bilimsel AraÅŸtÄ±rmalar</span>
        <h1>Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ±</h1>
        <div class="post-meta">
            <span>ğŸ“… 12 Åubat 2026</span>
            <span>â±ï¸ 8 dk okuma</span>
        </div>

        <div class="featured-image">
            <img src="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=600&fit=crop" alt="Semaglutide ve Kalp SaÄŸlÄ±ÄŸÄ±: SELECT Ã‡alÄ±ÅŸmasÄ± SonuÃ§larÄ±">
        </div>

        <div class="post-content">
            <p>2023 yÄ±lÄ±nda New England Journal of Medicine'da yayÄ±nlanan SELECT Ã§alÄ±ÅŸmasÄ±, semaglutid 2.4 mg'nin (Wegovy dozu) obez veya fazla kilolu kardiyovaskÃ¼ler hastalÄ±ÄŸÄ± olan bireylerde kalp-damar olaylarÄ±nÄ± azalttÄ±ÄŸÄ±nÄ± gÃ¶stermiÅŸtir. Bu Ã§alÄ±ÅŸmanÄ±n sonuÃ§larÄ±, obezite tedavisinde kardiyovaskÃ¼ler koruma boyutunu Ã¶n plana Ã§Ä±karmÄ±ÅŸtÄ±r.</p>

<div style="background: #FEF3C7; border: 1px solid #F59E0B; border-radius: 8px; padding: 1rem; margin: 1.5rem 0; font-size: 0.95rem; color: #92400E;">
<strong>âš ï¸ Ã–nemli AyrÄ±m:</strong> SELECT Ã§alÄ±ÅŸmasÄ±nda kullanÄ±lan semaglutid 2.4 mg, <strong>Wegovy</strong> (obezite endikasyonu) dozudur. <strong>Ozempic</strong> (maksimum 1 mg) yalnÄ±zca tip 2 diyabet tedavisi iÃ§in onaylanmÄ±ÅŸtÄ±r. Bu iki preparat aynÄ± etken maddeyi iÃ§ermekle birlikte doz ve endikasyon aÃ§Ä±sÄ±ndan farklÄ±dÄ±r.
</div>

<h2>SELECT Ã‡alÄ±ÅŸmasÄ± Nedir?</h2>
<p>SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), 17.604 katÄ±lÄ±mcÄ± ile gerÃ§ekleÅŸtirilen Ã§ok merkezli, randomize, Ã§ift kÃ¶r, plasebo kontrollÃ¼ bir Ã§alÄ±ÅŸmadÄ±r ğŸŸ¢ (RCT, n=17.604):</p>
<ul>
<li><strong>KatÄ±lÄ±mcÄ± profili</strong>: 45 yaÅŸ Ã¼stÃ¼, BMI â‰¥27 kg/mÂ², yerleÅŸik kardiyovaskÃ¼ler hastalÄ±ÄŸÄ± olan bireyler</li>
<li><strong>Temel Ã¶zellik</strong>: Diyabet tanÄ±sÄ± olmayan (HbA1c &lt;%6.5) ancak kardiyovaskÃ¼ler hastalÄ±ÄŸÄ± mevcut bireyler</li>
<li><strong>SÃ¼re</strong>: Ortalama 40 aylÄ±k (3.3 yÄ±l) takip</li>
<li><strong>YÃ¶ntem</strong>: Ã‡ift kÃ¶r, plasebo kontrollÃ¼, randomize</li>
</ul>
<h2>Ã‡alÄ±ÅŸmanÄ±n Temel BulgularÄ±</h2>
<h3>KardiyovaskÃ¼ler Olaylar</h3>
<p>Semaglutid kullanan grupta plasebo grubuna gÃ¶re (%6.5 vs %8.0):</p>
<ul>
<li><strong>%20 azalma</strong> ana kardiyovaskÃ¼ler olaylarda (MACE: KV Ã¶lÃ¼m + non-fatal MÄ° + non-fatal inme) â€” HR 0.80 (95% GA 0.72-0.90, p&lt;0.001) ğŸŸ¢</li>
<li><strong>Non-fatal miyokard infarktÃ¼sÃ¼</strong>: %28 azalma â€” HR 0.72 (95% GA 0.61-0.85) ğŸŸ¢</li>
<li><strong>KardiyovaskÃ¼ler Ã¶lÃ¼m</strong>: %15 azalma â€” HR 0.85 (95% GA 0.71-1.01, <strong>p=0.07, istatistiksel olarak anlamlÄ± deÄŸildir</strong>)</li>
<li><strong>TÃ¼m nedenlere baÄŸlÄ± mortalite</strong>: HR 0.81 (95% GA 0.71-0.93), ancak <strong>p=0.08, Ã¶nceden tanÄ±mlanmÄ±ÅŸ anlamlÄ±lÄ±k eÅŸiÄŸine ulaÅŸmamÄ±ÅŸtÄ±r</strong></li>
</ul>

<h3>Kilo KaybÄ± SonuÃ§larÄ±</h3>
<ul>
<li>Ortalama <strong>%9.4 kilo kaybÄ±</strong> (plaseboda %0.9) â€” 104. haftada</li>
<li>KatÄ±lÄ±mcÄ±larÄ±n <strong>%67'si</strong> %5'ten fazla kilo vermiÅŸtir</li>
</ul>
<p><em>Not: SELECT Ã§alÄ±ÅŸmasÄ±nda kilo kaybÄ±, STEP 1'e (%15) kÄ±yasla daha dÃ¼ÅŸÃ¼ktÃ¼r. Bu durum, katÄ±lÄ±mcÄ± popÃ¼lasyonunun farklÄ±lÄ±ÄŸÄ±ndan (daha yaÅŸlÄ±, yerleÅŸik KV hastalÄ±ÄŸÄ±) kaynaklanmaktadÄ±r.</em></p>
<h2>Semaglutid NasÄ±l Ã‡alÄ±ÅŸÄ±yor?</h2>
<h3>GLP-1 ReseptÃ¶r Agonisti</h3>
<p>Semaglutid, doÄŸal hormon GLP-1'i taklit etmektedir:</p>
<ul>
<li><strong>Ä°nsÃ¼lin salÄ±mÄ±nÄ±</strong> artÄ±rÄ±r (sadece kan ÅŸekeri yÃ¼ksekken)</li>
<li><strong>Glukagon salÄ±mÄ±nÄ±</strong> azaltÄ±r</li>
<li><strong>Mide boÅŸalmasÄ±nÄ±</strong> yavaÅŸlatÄ±r</li>
<li><strong>Beyindeki tokluk merkezini</strong> aktive eder</li>
</ul>

<h3>KardiyovaskÃ¼ler Koruma MekanizmalarÄ±</h3>
<p><strong>Direkt etkiler:</strong></p>
<ul>
<li>Kalp kas hÃ¼crelerindeki GLP-1 reseptÃ¶rleri Ã¼zerinden etki</li>
<li>Anti-inflamatuar etkiler (CRP'de %38.5 azalma)</li>
<li>Endotel fonksiyonunu iyileÅŸtirme</li>
</ul>
<p><strong>Ä°ndirekt etkiler:</strong></p>
<ul>
<li>Kilo kaybÄ±</li>
<li>Kan basÄ±ncÄ± dÃ¼ÅŸÃ¼ÅŸÃ¼</li>
<li>Trigliserit seviyelerinde azalma</li>
</ul><h2>Kilo KaybÄ±nÄ±n Kalp SaÄŸlÄ±ÄŸÄ±na Etkileri</h2>
<h3>Metabolik Ä°yileÅŸmeler</h3>
<ul>
<li><strong>Kan basÄ±ncÄ±</strong>: Sistolik kan basÄ±ncÄ±nda ortalama 3.8 mmHg fark (semaglutid vs plasebo) ğŸŸ¢</li>
<li><strong>Trigliseritler</strong>: %19.7 azalma</li>
<li><strong>HDL kolesterol</strong>: %6.2 artÄ±ÅŸ</li>
<li><strong>C-reaktif protein</strong>: %38.5 azalma ğŸŸ¢</li>
</ul>

<h3>Risk FaktÃ¶rlerinde DÃ¼zelme</h3>
<ul>
<li><strong>Diyabet geliÅŸim riski</strong>: HbA1c â‰¥%6.5'e ilerleme %73 azalmÄ±ÅŸtÄ±r (HR 0.27) ğŸŸ¢</li>
<li><strong>Kan ÅŸekeri kontrol</strong> parametrelerinde iyileÅŸme</li>
</ul>
<h2>TÃ¼rkiye'deki Durum ve Uygulanabilirlik</h2>
<p>TÃ¼rkiye'de obezite oranÄ± yaklaÅŸÄ±k %32'dir (OECD, 2024).</p>

<h3>EriÅŸim ve Maliyet</h3>
<ul>
<li>TÃ¼rkiye'de <strong>Ozempic</strong> (semaglutid maksimum 1 mg, diyabet endikasyonu) mevcuttur</li>
<li><strong>Wegovy</strong> (semaglutid 2.4 mg, obezite tedavisi) henÃ¼z ruhsatlandÄ±rÄ±lmamÄ±ÅŸtÄ±r</li>
<li>SGK kapsamÄ±nda yalnÄ±zca tip 2 diyabet endikasyonuyla sÄ±nÄ±rlÄ± kullanÄ±m mevcuttur</li>
<li>Obezite endikasyonuyla SGK kapsamÄ± bulunmamaktadÄ±r</li>
</ul>

<h3>Uygun Hasta Profili</h3>
<ul>
<li><strong>VKÄ° 30 kg/mÂ² Ã¼zeri</strong> obez bireyler</li>
<li><strong>VKÄ° 27 kg/mÂ² Ã¼zeri</strong> + komorbidite varlÄ±ÄŸÄ±</li>
<li><strong>KardiyovaskÃ¼ler risk faktÃ¶rleri</strong> bulunan kiÅŸiler</li>
<li><strong>Diyabet olmayan</strong> obez bireyler (SELECT popÃ¼lasyonu)</li>
</ul>
<h2>Yan Etkiler ve GÃ¼venlik</h2>
<h3>SÄ±k GÃ¶rÃ¼len Yan Etkiler</h3>
<ul>
<li><strong>Gastrointestinal</strong>: BulantÄ± (%44), kusma (%24), diyare (%30) ğŸŸ¢ (SELECT verileri)</li>
<li>Genelde hafif-orta ÅŸiddette</li>
<li>Ä°lk haftalarda daha sÄ±k gÃ¶rÃ¼lmekte, zamanla azalmaktadÄ±r</li>
<li>Kademeli doz artÄ±rÄ±mÄ±yla tolerabilite iyileÅŸmektedir</li>
</ul>

<h3>Ciddi Yan Etkiler</h3>
<ul>
<li><strong>Pankreatit</strong> riski (nadir)</li>
<li><strong>Safra kesesi</strong> problemleri (kolelitiyazis)</li>
<li><strong>BÃ¶brek fonksiyon</strong> bozukluÄŸu (dehidratasyon iliÅŸkili)</li>
<li><strong>Tiroid medÃ¼ller karsinom (MTC)</strong>: ğŸ”´ <strong>Hayvan Ã§alÄ±ÅŸmasÄ± uyarÄ±sÄ±</strong> â€” GLP-1 reseptÃ¶r agonistleri kemirgen modellerinde tiroid C-hÃ¼cresi tÃ¼mÃ¶rlerine neden olmuÅŸtur. Ä°nsanlarda bu risk doÄŸrulanmamÄ±ÅŸtÄ±r; ancak kiÅŸisel veya birinci derece aile Ã¶ykÃ¼sÃ¼nde MTC veya MEN2 sendromu bulunan kiÅŸilerde kontrendikedir.</li>
</ul>
<h2>Pratik Uygulama Ã–nerileri</h2>
<h3>Tedavi BaÅŸlamadan Ã–nce</h3>
<p><strong>KapsamlÄ± deÄŸerlendirme:</strong></p>
<ul>
<li>VKÄ° hesaplama</li>
<li>Komorbidite tarama</li>
<li>KardiyovaskÃ¼ler risk deÄŸerlendirmesi</li>
</ul>
<p><strong>Laboratuvar tetkikleri:</strong></p>
<ul>
<li>AÃ§lÄ±k kan ÅŸekeri ve HbA1c</li>
<li>Lipid profili</li>
<li>BÃ¶brek fonksiyon testleri</li>
</ul>

<h3>Tedavi SÃ¼reci</h3>
<ul>
<li><strong>BaÅŸlangÄ±Ã§ dozu</strong>: 0.25 mg haftalÄ±k</li>
<li><strong>Doz artÄ±rÄ±mÄ±</strong>: 4 hafta arayla kademeli</li>
<li><strong>Hedef doz</strong>: 2.4 mg haftalÄ±k (Wegovy dozu)</li>
<li><strong>DÃ¼zenli takip</strong>: AylÄ±k kontroller</li>
</ul>

<h3>YaÅŸam TarzÄ± DeÄŸiÅŸiklikleri</h3>
<ul>
<li><strong>Beslenme danÄ±ÅŸmanlÄ±ÄŸÄ±</strong> alÄ±nmasÄ± Ã¶nerilmektedir</li>
<li><strong>DÃ¼zenli egzersiz</strong> programÄ± uygulanmalÄ±dÄ±r</li>
<li><strong>DavranÄ±ÅŸ deÄŸiÅŸikliÄŸi</strong> desteÄŸi aranmalÄ±dÄ±r</li>
<li><strong>Sosyal destek</strong> sistemlerinden faydalanÄ±lmalÄ±dÄ±r</li>
</ul>
<h2>Kimler Ä°Ã§in Uygun DeÄŸil?</h2>
<h3>Kesin Kontrendikasyonlar</h3>
<ul>
<li><strong>Tip 1 diyabet</strong></li>
<li><strong>Gebelik ve emzirme</strong> dÃ¶nemi</li>
<li><strong>Diyabetik ketoasidoz</strong> Ã¶ykÃ¼sÃ¼</li>
<li><strong>Ciddi gastroparezi</strong></li>
<li><strong>KiÅŸisel veya ailevi MTC/MEN2 Ã¶ykÃ¼sÃ¼</strong></li>
</ul>

<h3>Dikkatli KullanÄ±m Gereken Durumlar</h3>
<ul>
<li><strong>BÃ¶brek yetmezliÄŸi</strong></li>
<li><strong>KaraciÄŸer hastalÄ±ÄŸÄ±</strong></li>
<li><strong>Pankreatit Ã¶ykÃ¼sÃ¼</strong></li>
<li><strong>Safra kesesi hastalÄ±ÄŸÄ±</strong></li>
</ul>
<h2>Ekonomik DeÄŸerlendirme</h2>
<h3>Maliyet-Etkinlik</h3>
<ul>
<li><strong>YÃ¼ksek ilaÃ§ maliyeti</strong> vs. <strong>uzun vadeli saÄŸlÄ±k faydalarÄ±</strong></li>
<li><strong>KardiyovaskÃ¼ler olaylarÄ±n</strong> Ã¶nlenmesi</li>
<li><strong>Diyabet geliÅŸiminin</strong> engellenmesi</li>
<li><strong>Genel saÄŸlÄ±k harcamalarÄ±nda</strong> azalma potansiyeli</li>
</ul>

<h2>Gelecek Perspektifi</h2>
<h3>Devam Eden AraÅŸtÄ±rmalar</h3>
<ul>
<li><strong>FLOW Ã§alÄ±ÅŸmasÄ±</strong>: BÃ¶brek hastalÄ±ÄŸÄ± progresyonunda %24 azalma gÃ¶sterilmiÅŸtir (HR 0.76, RCT) ğŸŸ¢</li>
<li><strong>NÃ¶rodejeneratif hastalÄ±klar</strong>: Alzheimer hastalÄ±ÄŸÄ± araÅŸtÄ±rmalarÄ± devam etmektedir ğŸ”´ (faz 3 Ã¶ncesi)</li>
<li><strong>KaraciÄŸer yaÄŸlanmasÄ± (MASLD)</strong>: Faz 2 Ã§alÄ±ÅŸmalarda olumlu sonuÃ§lar ğŸŸ¡</li>
<li><strong>Kanser riski</strong>: Uzun vadeli deÄŸerlendirmeler devam etmektedir</li>
</ul>

<h3>TÃ¼rkiye'deki Beklentiler</h3>
<ul>
<li><strong>Wegovy ruhsatlandÄ±rmasÄ±</strong> beklentisi</li>
<li><strong>SGK kapsamÄ±na</strong> alÄ±nma sÃ¼reci</li>
<li><strong>Obezite tedavi merkezleri</strong> geliÅŸimi</li>
<li><strong>Multidisipliner yaklaÅŸÄ±m</strong> yaygÄ±nlaÅŸmasÄ±</li>
</ul>
<h2>SonuÃ§ ve Ã–neriler</h2>
<p>SELECT Ã§alÄ±ÅŸmasÄ±, semaglutid 2.4 mg'nin yerleÅŸik kardiyovaskÃ¼ler hastalÄ±ÄŸÄ± olan obez/fazla kilolu bireylerde majÃ¶r kardiyovaskÃ¼ler olaylarÄ± %20 azalttÄ±ÄŸÄ±nÄ± gÃ¶stermiÅŸtir. Ancak kardiyovaskÃ¼ler Ã¶lÃ¼m ve tÃ¼m nedenlere baÄŸlÄ± mortalite azalmasÄ± istatistiksel anlamlÄ±lÄ±ÄŸa ulaÅŸmamÄ±ÅŸtÄ±r. Bu sonuÃ§lar, obezite tedavisinde kardiyovaskÃ¼ler risk yÃ¶netiminin Ã¶nemini vurgulamaktadÄ±r.</p>
<p><strong>Ã–nemli hatÄ±rlatmalar:</strong></p>
<ul>
<li>Ä°laÃ§ tedavisi tek baÅŸÄ±na yeterli deÄŸildir; yaÅŸam tarzÄ± deÄŸiÅŸiklikleriyle birleÅŸtirilmelidir</li>
<li>DÃ¼zenli takip gereklidir</li>
<li>Yan etkiler dikkatle izlenmelidir</li>
<li>Tedavi kararÄ± bireyselleÅŸtirilmeli, uzman hekim tarafÄ±ndan verilmelidir</li>
</ul>
<p>Obezite ve kardiyovaskÃ¼ler saÄŸlÄ±k konularÄ±nda uzman hekiminizle gÃ¶rÃ¼ÅŸerek size en uygun tedavi planÄ±nÄ± belirleyin.</p>
        </div>

        <div class="key-points">
            <h4>ğŸ“Œ Ã–nemli Noktalar</h4>
            <ul>
<li>SELECT Ã§alÄ±ÅŸmasÄ± (n=17.604, RCT) semaglutid 2.4 mg'nin MACE'yi %20 azalttÄ±ÄŸÄ±nÄ± gÃ¶stermiÅŸtir (HR 0.80, p&lt;0.001) ğŸŸ¢</li>
<li>KardiyovaskÃ¼ler Ã¶lÃ¼m (HR 0.85, p=0.07) ve tÃ¼m nedenlere baÄŸlÄ± mortalite (HR 0.81, p=0.08) istatistiksel anlamlÄ±lÄ±ÄŸa ulaÅŸmamÄ±ÅŸtÄ±r</li>
<li>Ortalama %9.4 kilo kaybÄ± ile birlikte metabolik parametrelerde iyileÅŸme saÄŸlanmÄ±ÅŸtÄ±r</li>
<li>Ozempic (maks 1 mg) â‰  Wegovy (2.4 mg): SELECT Ã§alÄ±ÅŸmasÄ± Wegovy dozuyla yapÄ±lmÄ±ÅŸtÄ±r</li>
<li>Tedavi Ã¶ncesi mutlaka uzman hekim deÄŸerlendirmesi ve dÃ¼zenli takip gereklidir</li>
</ul>
        </div>

        <div class="disclaimer">
            âš ï¸ <strong>Ã–nemli:</strong> Bu iÃ§erik sadece bilgilendirme amaÃ§lÄ±dÄ±r ve tÄ±bbi tavsiye yerine geÃ§mez. Herhangi bir tedaviye baÅŸlamadan Ã¶nce mutlaka doktorunuza danÄ±ÅŸÄ±n.
        </div>

        <div class="sources">
            <h4>ğŸ“š Kaynaklar</h4>
            <ol>
<li>Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." <em>New England Journal of Medicine</em>, 2023; 389(24):2221-2232. DOI: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2307563" target="_blank" rel="noopener">10.1056/NEJMoa2307563</a></li>
<li>Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." <em>New England Journal of Medicine</em>, 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183</li>
<li>Perkovic V, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)." <em>New England Journal of Medicine</em>, 2024; 391(2):109-121. DOI: 10.1056/NEJMoa2403347</li>
<li>Kosiborod MN, et al. "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity." <em>New England Journal of Medicine</em>, 2023; 389(12):1069-1084. DOI: 10.1056/NEJMoa2306963</li>
<li>Ryan DH, et al. "SELECT trial: semaglutide effects on cardiovascular outcomes â€” key secondary endpoints." <em>Circulation</em>, 2024. DOI: 10.1161/CIRCULATIONAHA.123.067747</li>
</ol>
        </div>

        <div class="share-section">
            <p><strong>Bu yazÄ±yÄ± paylaÅŸÄ±n</strong></p>
            <div class="share-buttons">
                <a href="https://twitter.com/intent/tweet?text=Semaglutide%20ve%20Kalp%20Sa%C4%9Fl%C4%B1%C4%9F%C4%B1%3A%20SELECT%20%C3%87al%C4%B1%C5%9Fmas%C4%B1%20Sonu%C3%A7lar%C4%B1" class="share-btn twitter" target="_blank">Twitter</a>
                <a href="https://www.linkedin.com/sharing/share-offsite/" class="share-btn linkedin" target="_blank">LinkedIn</a>
                <a href="https://wa.me/?text=Semaglutide%20ve%20Kalp%20Sa%C4%9Fl%C4%B1%C4%9F%C4%B1%3A%20SELECT%20%C3%87al%C4%B1%C5%9Fmas%C4%B1%20Sonu%C3%A7lar%C4%B1" class="share-btn whatsapp" target="_blank">WhatsApp</a>
            </div>
        </div>

        <div class="cta-section">
            <h3>KiÅŸisel saÄŸlÄ±k deÄŸerlendirmenizi yapÄ±n</h3>
            <p>2 dakikada size Ã¶zel saÄŸlÄ±k Ã¶nerileri alÄ±n</p>
            <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
        </div>
    </article>

    <footer><p style="font-size:0.85rem;font-style:italic;opacity:0.7;margin-bottom:0.5rem;">TÃ¼rkiye uzun yaÅŸasÄ±n diye.</p><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
<script src="/scripts/premium-animations.js"></script>
</body>
</html>